| Notes: |
Editorial -- Export Date: 1 April 2022 -- Funding details: ACEA Biosciences -- Funding details: Atara Biotherapeutics -- Funding details: China Agricultural Research System, CARS -- Funding text 1: Disclosures: P.S.A. has received research funding from ATARA Biotherapeutics and ACEA Biosciences; has served on the Scientific Advisory Board or as consultant to ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, and Takeda Therapeutics; and has patents, royalties, and intellectual property on mesothelin-targeted CARs and other T-cell therapies, method for detection of cancer cells using virus, and pending patent applications on T-cell therapies. All other authors reported no conflicts of interest. -- Source: Scopus |
